These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8571474)

  • 1. [The efficacy of bacteriophage preparations in treating inflammatory urologic diseases].
    Perepanova TS; Darbeeva OS; Kotliarova GA; Kondrat'eva EM; Maĭskaia LM; Malysheva VF; Baĭguzina FA; Grishkova NV
    Urol Nefrol (Mosk); 1995; (5):14-7. PubMed ID: 8571474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sensitivity of the causative agents of suppurative-inflammatory diseases to medical bacteriophages].
    Men'shikov DD; Ianisker GIa; Savel'eva GF; Bialik IF; Maksimov IuM
    Antibiotiki; 1980 May; 25(5):356-9. PubMed ID: 6446257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new phage typing scheme for Proteus mirabilis and Proteus vulgaris strains. 1. Morphological analysis.
    Sekaninová G; Hofer M; Rychlík I; Pillich J; Kolárová M; Zajícová V; Kubícková D
    Folia Microbiol (Praha); 1994; 39(5):381-6. PubMed ID: 7729773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms].
    Kochetkova VA; Mamontov AS; Moskovtseva RL; Erastova EI; Trofimov EI; Popov MI; Dzhubalieva SK
    Sov Med; 1989; (6):23-6. PubMed ID: 2799488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacteriophage typing of Proteus mirabilis, Proteus vulgaris, and Proteus morganii.
    Schmidt WC; Jeffries CD
    Appl Microbiol; 1974 Jan; 27(1):47-53. PubMed ID: 4589141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
    Wright A; Hawkins CH; Anggård EE; Harper DR
    Clin Otolaryngol; 2009 Aug; 34(4):349-57. PubMed ID: 19673983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of therapeutic potential of the experimental pseudomonas bacteriophage preparation.
    Dzuliashvili M; Gabitashvili K; Golidjashvili A; Hoyle N; Gachechiladze K
    Georgian Med News; 2007 Jun; (147):81-8. PubMed ID: 17660609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new bacteriophage typing scheme for Proteus mirabilis and Proteus vulgaris strains. 3. Analysis of lytic properties.
    Sekaninová G; Rychlík I; Kolárová M; Pillich J; Seménka J; Zajícová V
    Folia Microbiol (Praha); 1998; 43(2):136-40. PubMed ID: 9721605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of polyvalent bacteriophages specific to uropathogenic Proteus mirabilis strains based on the host range pattern and RFLP.
    Maszewska A; Wójcik E; Ciurzyńska A; Wojtasik A; Piątkowska I; Dastych J; Różalski A
    Acta Biochim Pol; 2016; 63(2):303-10. PubMed ID: 26730411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of Proteus mirabilis by bacteriophage typing and the Dienes reaction.
    Hickman FW; Farmer JJ
    J Clin Microbiol; 1976 Mar; 3(3):350-8. PubMed ID: 773962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of microbiological monitoring of infective agents in an urological hospital in the selection of antibacterial therapy regimens].
    Derevianko II; Nefedova LA; Lavrinova LN; Prudnikova SA
    Urologiia; 2001; (4):11-5. PubMed ID: 11569227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What happens when the child gets bacteriophage per os?].
    Pagava KI; Gachechiladze KK; Korinteli IA; Dzuliashvili MG; Alavidze ZI; Hoyle N; Metskhvarishvili GD
    Georgian Med News; 2011; (196-197):101-5. PubMed ID: 21873760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New perspectives of the phage therapy].
    Eyer L; Pantůcek R; Růzicková V; Doskar J
    Klin Mikrobiol Infekc Lek; 2007 Dec; 13(6):231-5. PubMed ID: 18320502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phage therapy: past history and future prospects.
    Carlton RM
    Arch Immunol Ther Exp (Warsz); 1999; 47(5):267-74. PubMed ID: 10604231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results.
    Slopek S; Durlakowa I; Weber-Dabrowska B; Kucharewicz-Krukowska A; Dabrowski M; Bisikiewicz R
    Arch Immunol Ther Exp (Warsz); 1983; 31(3):293-327. PubMed ID: 6651485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteriophage therapy: an alternative to conventional antibiotics.
    Mathur MD; Vidhani S; Mehndiratta PL
    J Assoc Physicians India; 2003 Jun; 51():593-6. PubMed ID: 15266928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of Proteus mirabilis and Proteus vulgaris strains by means of proticine typing: a longitudinal epidemiological study.
    Sekaninová G; Kolárová M
    Cent Eur J Public Health; 1996 May; 4(2):98-101. PubMed ID: 8996720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Some immunological changes in children with bacterial infections treated with bacteriophages].
    Pagava KI; Metskhvarishvili GD; Gachechiladze KK; Korinteli IA; Khoĭle N; Dzuliashvili MG
    Georgian Med News; 2012 Nov; (212):64-9. PubMed ID: 23221141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GROWTH OF MALE-SPECIFIC BACTERIOPHAGE IN PROTEUS MIRABILIS HARBORING F-GENOTES DERIVED FROM ESCHERICHIA COLI.
    HORIUCHI K; ADELBERG EA
    J Bacteriol; 1965 May; 89(5):1231-6. PubMed ID: 14292991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lytic bacteriophage PM16 specific for Proteus mirabilis: a novel member of the genus Phikmvvirus.
    Morozova V; Kozlova Y; Shedko E; Kurilshikov A; Babkin I; Tupikin A; Yunusova A; Chernonosov A; Baykov I; Кondratov I; Kabilov M; Ryabchikova E; Vlassov V; Tikunova N
    Arch Virol; 2016 Sep; 161(9):2457-72. PubMed ID: 27350061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.